BioSig Technologies Announces PURE-EP System Clinical Data

BioSig Technologies, Inc. announced that clinical data from the company’s PURE EP System, a biomedical signal processing platform designed to improve the efficacy and efficiency of ablation procedures, will be featured in two presentations (abstracts) at the annual Heart Rhythm 2021 convention

The first presentation was co-authored by Pedram Kazemian, M.D. et al., of Deborah Heart and Lung Center in Browns Mills, New Jersey, is titled, “Post-Ablation Bipolar Voltage By PURE EP(tm) As a Marker Of Transmural Lesion.”

The second abstract was co-authored by Jonathan Salas, B.S.; Pasquale Santangeli, M.D.; David Callans, M.D.; Francis E. Marchlinski, M.D.; Cory M. Tschabrunn, Ph.D. of University of Pennsylvania in Philadelphia, Pennsylvania, is titled, “Atrial Unipolar Electrogram Filtering to Better Delineate EGM Amplitude and Morphology During Radiofrequency Ablation.”
BioSig’s PURE EP System is designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals during complex ablation procedures.
The company completed enrollment for its second multi-center clinical trial in April 2021 and looks forward to sharing PURE EP’s most recent clinical data in-person at the Heart Rhythm 2021 convention on July 28-31, 2021.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”